Obbligazione Barclay PLC 4.5% ( US06738JP321 ) in USD

Barclay PLC

100 USD ▼

Regno Unito

US06738JP321 ( in USD )

4.5% per anno ( pagato 2 volte l'anno)

14/04/2024 - Obbligazione è scaduto

Prospetto opuscolo dell'obbligazione Barclays PLC US06738JP321 in USD 4.5%, scaduta

1 000 USD

71 000 USD

06738JP32

A ( Upper medium grade - Investment-grade )

A1 ( Upper medium grade - Investment-grade )

Barclays PLC è una banca multinazionale britannica che offre una vasta gamma di servizi finanziari a clienti privati, aziende e istituzioni in tutto il mondo.

The Obbligazione issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06738JP321, pays a coupon of 4.5% per year.
The coupons are paid 2 times per year and the Obbligazione maturity is 14/04/2024

The Obbligazione issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06738JP321, was rated A1 ( Upper medium grade - Investment-grade ) by Moody's credit rating agency.

The Obbligazione issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06738JP321, was rated A ( Upper medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency.

Pricing Supplement 13Y 4.5% Fixed Note
Page 1 of 9
424B2 1 d424b2.htm PRICING SUPPLEMENT 13Y 4.5% FIXED NOTE
CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities Offered

Maximum Aggregate Offering Price
Amount of Registration Fee(1)
Global Medium-Term Notes, Series A

$71,000
$8.24
(1) Calculated in accordance with Rule 457(r) of the Securities Act of 1933.
http://www.sec.gov/Archives/edgar/data/312070/000119312511096267/d424b2.htm
4/13/2011

Pricing Supplement 13Y 4.5% Fixed Note
Page 2 of 9
Pricing Supplement dated April 11, 2011
Filed Pursuant to Rule 424(b)(2)
(To Prospectus dated August 31, 2010 and
Registration No. 333-169119
the Prospectus Supplement dated August 31, 2010)
U
opt(bcqlidtr S
Mf
h
D
Ooa
U1
mihe
ac
w
yn)ais$71
your
ey
tal
y co
tober
ner
thee
Br
sted od
ar
et
pric
market 000
dium
yment)f
lendar
on T
t
mec
uotationy
aine
o
adjusteds
claysa
sapproved
ing
ansactions 4
princ
Int
he
anysi
b
nominatioe
om
xercises
earllo
resale 50%
rmpal
due
ecease
C
inm
ns:
rest
dby
Day
ystem
or
Uf S
t
upp s
MR
Notes
ForCaP
any FIXE
Notes
adea
all
a
apitalp
heseo
mencing
w
bene
ric
I
N S
ubject
n
Interest
te:e
ount
lement
ot t4
o
nc
transactionD
he
inimum
n
w
ficial
holder
dditio
to
ortion
in
es R
eries
to
Rate
O
ills
nal
will
of
ecurities
aft AT
A
the
de
50%of
dt
e
there
securitiesi t
he
t E
c
Public
o r
Notes
ctober
repay
ownerse
he NOT
ei
Type:t
ad
nitiaF
Interest
1
ir4
hose
ails
Convention:lle
these
receive
xchangesa
N
re
AgentES
Original
ncludin
ixed
nominations
2011
initiN
st
otes
's
comm
or
ale o
al fDU
Issue
ditworthine
g
Rate
of
Payme
otes
six
30/360C m
in
garding
eterminedNt
sale E
D
s
nt
commissi s
anyO
t
and
issions A
o
pr
D
e
any
he
ommi
ons
hat
otesr
quotationPRI
ate:f
prior
onths
S
t sA
B
US$1000
atetus
his
In :
o
ssion
use
UnlessL
p
rincip
iginal
nding
Settlement:o
t
calen
froma
p 14
ril
aln
he
prior
Dtll
we1
and
(1)
ystemt
dar
rvivorT4
arclaysi
o'
P
heor20
ys
C
or B
prot
Trade
thet
N
ricingh
e;a
addition 24
D
M
Maturi
e
a
Or;
B
roce
Issuer
B
oura Prin
2011
ank
ntegral
Monthly
ty
eitherr Pr
P
ection
ate:
date
an
ookd
ption
eds p
meto
portion cipal
LC
April
aturity
Date
of
·sn
the
agent th
ee
B
equal
o
claysf
Si ett
supplementC1
the
"
try;ocisA
incipal
The1
ultiples
Quarte
Dater
p
De
1t mount:
PN
rovidedoS
er
arclay
hese otes
af
apital
nforms t
rlyu
followsi m
2011
U
uritiesI
ng
equest
mitted
B
55% of
and
ruthful
nc
you oU
are
rvivor
the
scription
Transferab
ankor
or
t S$71
rotection'
leP
E P
not
aturity
Maturity
S$1000
Semi
sd
Theo
thexcO
r
dollar
f S
LC
p
o A
eath
r a
i
commissions
m 000
erce
depe
ption:
o
ight
herwise fto
Per
to
change
anotheri t
Listing:N
pleteo
n Issu
ntage:
either
nds
Date:
he
mount
urvivor
ncipalft '
payA
thereafter
nnuallys
The
ote
Aos
he er:
If
direct
onpril
B
Upon
of1
ny
ur a
O
el n
N00B
ly
the
exercise
amount
aff
confi ar
you
linga
14
ption
otes
%rcclays
hold
or
usiness
Annual
request
beneficial
this
indiv
"1
of
Commissiont
o
represe i
bne
hn
iliates t
bility
2024
Dl
willey
by
55%
nor
m
mation B
he
of
ay:
dual
low
nooank
indirecp
optiont
aytly
B
the
ownere
fb
98
note
any
tation a

uostf
w
Be4
cessionssoe
alP
t
ill
5 t
e L
Notes
an
CUSIP:
ayable
he
%
or
tatetC
to
rclays
New
be
xercise
listed
T
he
his Issue
m
bY
in
No
b
usinesso
feet
$15s
p
his at
Bank
ork
uthorized
tes
y
op a
Dnay
al a
50
to
contr P
p
subject
ny
$7ry
ricing rice:
urity
ligation

arrears
1
per
securities
ricing o
06738JP32o
to:
U$
other
c
is f
PLC
In
represe·
holder1d
a t
S
000 100%
you
ao
ev
naocfwill
nys
SIN:
Londo
e
rovidedpt
$1
000n
ry
tative
s
Convention
ealers : Series:
r
supplementeceive
third
atisfy
14o
uch
hese
100 f
T
ommission
riminali
supplement p
tht
N
securitie
princio
ni art
its
he
ermitted
s
50
he d
e
pal
has
mby
Euro
day
otes
Notes
Followa
a G
at
i
$69ao
i
xch
Note
ffenselobal
n
m
rkele
oblig
US06738JP3f
ollar
ast
einga
ng
ppr ast
and
21
A
benefi
were
a
899
W
u a
s
ny
nge5
ount
will
e 100
ny
ations
Other
pril
cial
mount
or
0not
oved
resal
ed o
me r
a
in %
as
and
cquired
and
y of
be
use
a
http://www.sec.gov/Archives/edgar/data/312070/000119312511096267/d424b2.htm
4/13/2011

Pricing Supplement 13Y 4.5% Fixed Note
Page 3 of 9
The Notes constitute our direct, unconditional, unsecured and unsubordinated obligations and are not deposit
liabilities of Barclays Bank PLC and are not insured by the U.S. Federal Deposit Insurance Corporation or any other
governmental agency of the United States, the United Kingdom or any other jurisdiction.
Investing in the Notes involves a number of risks. See "Risk Factors" beginning on page S-5 of the prospectus
supplement and "Selected Risk Factors" below. We urge you to consult your investment, legal, tax, accounting and
other advisers and to invest in the Notes only after you and your advisors have carefully considered the suitability of
an investment in the Notes in light of your particular circumstances.
Barclays Bank PLC has filed a registration statement (including a prospectus) with the SEC for the offering to which
this pricing supplement relates. Before you invest, you should read the prospectus dated August 31, 2010, the
prospectus supplement dated August 31, 2010, and other documents Barclays Bank PLC has filed with the SEC for
more complete information about Barclays Bank PLC. and this offering. Buyers should rely upon this pricing
supplement, the prospectus, the prospectus supplement, and any relevant free writing prospectus for complete details.
You may get these documents and other documents Barclays Bank PLC has filed for free by visiting EDGAR on the
SEC website at www.sec.gov, and you may also access the prospectus and prospectus supplement through the links
below:

·
Prospectus dated August 31, 2010:
http://www.sec.gov/Archives/edgar/data/312070/000119312510201448/df3asr.htm

·
Prospectus Supplement dated August 31, 2010:
http://www.sec.gov/Archives/edgar/data/312070/000119312510201604/d424b3.htm
Our Central Index Key, or CIK, on the SEC website is 1-10257.
Alternatively, Barclays Capital Inc. or any agent or dealer participating in this offering will arrange to send you this
pricing supplement, the prospectus, the prospectus supplement and any relevant free writing prospectus if you
request it by calling your Barclays Capital Inc. sales representative, such dealer or 1-888-227-2275 (Extension 2-3430).
A copy of the prospectus may be obtained from Barclays Capital Inc., 745 Seventh Avenue--Attn: US InvSol
Support, New York, NY 10019.
You may revoke your offer to purchase the Notes at any time prior to the time at which we accept such offer by notifying the
applicable agent. We reserve the right to change the terms of, or reject any offer to purchase the Notes prior to their issuance.
In the event of any changes to the terms of the Notes, we will notify you and you will be asked to accept such changes in
connection with your purchase. You may also choose to reject such changes in which case we may reject your offer to
purchase.
As used in this term sheet, the "Company," "we," "us," or "our" refers to Barclays Bank PLC.
http://www.sec.gov/Archives/edgar/data/312070/000119312511096267/d424b2.htm
4/13/2011

Pricing Supplement 13Y 4.5% Fixed Note
Page 4 of 9
SELECTED RISK FACTORS
An investment in the Notes involves significant risks. You should read the risks summarized below in connection with,
and the risks summarized below are qualified by reference to, the risks described in more detail in the "Risk Factors"
section beginning on page S-5 of the prospectus supplement. We urge you to consult your investment, legal, tax,
accounting and other advisers and to invest in the Notes only after you and your advisors have carefully considered
the suitability of an investment in the Notes in light of your particular circumstances.

·
Issuer Credit Risk--The Notes are our unsecured debt obligations, and are not, either directly or indirectly, an
obligation of any third party. Any payment to be made on the Notes, including any principal protection provided at
maturity, depends on our ability to satisfy our obligations as they come due. As a result, the actual and perceived

creditworthiness of Barclays Bank PLC may affect the market value of the Notes and, in the event we were to
default on our obligations, you may not receive the principal protection or any other amounts owed to you under
the terms of the Notes.

·
Certain Built-In Costs Are Likely to Adversely Affect the Value of the Notes Prior to Maturity--Although
you will not receive less than the principal amount of the Notes if you hold the Notes to maturity (subject to Issuer
credit risk), the Original Issue Price of the Notes includes the agent's commission and the cost of hedging our

obligations under the Notes through one or more of our affiliates. As a result, assuming no change in market
conditions or any other relevant factor, the price, if any, at which Barclays Capital Inc. and other affiliates of
Barclays Bank PLC will be willing to purchase Notes from you in secondary market transactions may be lower
than the Original Issue Price, and any sale prior to the Maturity Date could result in a substantial loss to you.

·
Potential Conflicts--We and our affiliates play a variety of roles in connection with the issuance of the Notes,

including hedging our obligations under the Notes. In performing these duties, the economic interests of our
affiliates of ours are potentially adverse to your interests as an investor in the Notes.
In addition, Barclays Wealth, the wealth management division of Barclays Capital Inc., may arrange for the sale of
the Notes to certain of its clients. In doing so, Barclays Wealth will be acting as agent for Barclays Bank PLC and
may receive compensation from Barclays Bank PLC in the form of discounts and commissions. The role of
Barclays Wealth as a provider of certain services to such customers and as agent for Barclays Bank PLC in
connection with the distribution of the Notes to investors may create a potential conflict of interest, which may be
adverse to such clients. Barclays Wealth is not acting as your agent or investment adviser, and is not representing
you in any capacity with respect to any purchase of Notes by you. Barclays Wealth is acting solely as agent for
Barclays Bank PLC. If you are considering whether to invest in the Notes through Barclays Wealth, we strongly
urge you to seek independent financial and investment advice to assess the merits of such investment.

·
Lack of Liquidity--The Notes will not be listed on any securities exchange. Barclays Capital Inc. and other
affiliates of Barclays Bank PLC intend to make a secondary market for the Notes but are not required to do so, and
may discontinue any such secondary market making at any time, without notice. Even if there is a secondary
market, it may not provide enough liquidity to allow you to trade or sell the Notes easily. Because other dealers are

not likely to make a secondary market for the Notes, the price at which you may be able to trade your Notes is
likely to depend on the price, if any, at which Barclays Capital Inc. and other affiliates of Barclays Bank PLC are
willing to buy the Notes. The Notes are not designed to be short-term trading instruments. Accordingly, you should
be able and willing to hold your Notes to maturity.

·
Many Economic and Market Factors Will Impact the Value of the Notes--The value of the Notes will be

affected by a number of economic and market factors that may either offset or magnify each other, including:

·
the time to maturity of the Notes;

·
interest and yield rates in the market generally;

·
a variety of economic, financial, political, regulatory or judicial events; and

·
our creditworthiness, including actual or anticipated downgrades in our credit ratings.

PS1
http://www.sec.gov/Archives/edgar/data/312070/000119312511096267/d424b2.htm
4/13/2011

Pricing Supplement 13Y 4.5% Fixed Note
Page 5 of 9
DESCRIPTION OF SURVIVOR'S OPTION
Upon request by the authorized representative of the beneficial owner of the Notes, Barclays Bank PLC will repay those
Notes prior to the Maturity Date following the death of the beneficial owner of the Notes (the "Survivor's Option"),
provided such Notes were acquired by the deceased beneficial owner at least six months prior to the date of the request. Upon
the valid exercise of the Survivor's Option and the proper tender of the Notes for repayment, Barclays Bank PLC will repay
such Notes, in whole or in part, at a price equal to 100% of the principal amount of the deceased beneficial owner's beneficial
interest in the Notes plus accrued and unpaid interest to the date of repayment. For purposes of this section, a beneficial
owner of Notes is a person who has the right, immediately prior to such person's death, to receive the proceeds from the
disposition of such Notes, as well as the right to receive payment of the principal of the Notes.
To be valid, the Survivor's Option must be exercised by or on behalf of the person who has authority to act on behalf of the
deceased beneficial owner of the Notes under the laws of the applicable jurisdiction (including, without limitation, the
personal representative of or the executor of the estate of the deceased beneficial owner or the surviving joint owner with the
deceased beneficial owner).
The death of a person holding a beneficial ownership interest in the Notes: (1) with any person in a joint tenancy with right of
survivorship; or (2) with his or her spouse in tenancy by the entirety, tenancy in common, as community property or in any
other joint ownership arrangement, will be deemed the death of a beneficial owner of those Notes, and the entire principal
amount of the Notes (subject to the limitations described below) held in this manner will be subject to repayment by Barclays
Bank PLC upon request. However, the death of a person holding a beneficial ownership interest in Notes as tenant in
common with a person other than his or her spouse will be deemed the death of a beneficial owner only with respect to such
deceased person's interest in the Notes, and only the deceased beneficial owner's percentage interest in the principal amount
of the Notes will be subject to repayment.
If the ownership interest in the Notes is held by a nominee for a beneficial owner or by a custodian under a Uniform Gifts to
Minors Act or Uniform Transfer to Minors Act, or by a trustee of a trust, or by a guardian or committee for a beneficial
owner, the death of the beneficial owner of the Notes will constitute death of the beneficial owner for purposes of the
Survivor's Option, if the beneficial ownership interest can be established to the satisfaction of Barclays Bank PLC. In these
cases, the death of the nominee, custodian, trustee, guardian or committee will not be deemed the death of the beneficial
owner of the Notes for purposes of the Survivor's Option.
Barclays Bank PLC has the discretionary right to limit the aggregate principal amount of the Notes as to which exercises of
the Survivor's Option will be accepted by it from all authorized representatives of deceased beneficial owners in any calendar
year, to an amount equal to 2.0% of the aggregate amount of the Notes, outstanding as of the end of the most recent calendar
year.
Barclays Bank PLC also has the discretionary right to limit to $250,000 the aggregate principal amount of Notes as to which
exercises of the Survivor's Option will be accepted by Barclays Bank PLC from the authorized representative for any
individual deceased beneficial owner of such notes in any calendar year. In addition, Barclays Bank PLC will not permit the
exercise of the Survivor's Option (a) for a principal amount less than $1,000, or (b) if such exercise will result in a beneficial
ownership interest in a note with a principal amount of less than $1,000 outstanding.
An otherwise valid election to exercise the Survivor's Option may not be withdrawn. Elections to exercise the Survivor's
Option will be accepted in the order that they are received and approved by Barclays Bank PLC, except for any election the
acceptance of which would contravene any of the limitations described above. Notes accepted for repayment through the
exercise of the Survivor's Option will be repaid on the first Interest Payment Date that occurs 60 or more calendar days after
the date of the acceptance and approval by Barclays Bank PLC. Each tendered Note that is not accepted in any calendar year
due to the application of any of the limitations described in the preceding paragraph will be deemed to be tendered in the
following calendar year in the order in which all such Notes were originally tendered. If a Note tendered through a valid
exercise of the Survivor's Option is not accepted by Barclays Bank PLC, the trustee, upon receipt of a valid written
instruction from Barclays Bank PLC or its agent, will deliver a notice to the registered holder that states the reason that Note
has not been accepted for repayment.
To obtain repayment of the Notes pursuant to exercise of the Survivor's Option, the deceased beneficial owner's authorized
representative must complete the Survivor's Option form of notice ("Form of Notice") and provide the following items to the
broker or other entity through which the beneficial interest in the Notes is held by the deceased beneficial owner:

·
appropriate evidence satisfactory to Barclays Bank PLC that:

(1)
the deceased was the beneficial owner of the Notes at the time of death and his or her interest in the Notes

was acquired by the deceased beneficial owner at least six months prior to the request for repayment,

http://www.sec.gov/Archives/edgar/data/312070/000119312511096267/d424b2.htm
4/13/2011

Pricing Supplement 13Y 4.5% Fixed Note
Page 6 of 9

(2)
the death of the beneficial owner has occurred and the date of death, and

(3)
the representative has authority to act on behalf of the deceased beneficial owner;

PS2
http://www.sec.gov/Archives/edgar/data/312070/000119312511096267/d424b2.htm
4/13/2011

Pricing Supplement 13Y 4.5% Fixed Note
Page 7 of 9
·
if the beneficial interest in the Notes is held by a nominee or trustee of, custodian for, or other person in a similar

capacity to, the deceased beneficial owner, evidence satisfactory to Barclays Bank PLC from the nominee, trustee,
custodian or similar person attesting to the deceased's beneficial ownership of that Notes;

·
a written request for repayment signed by the authorized representative of the deceased beneficial owner with the
signature guaranteed by a firm that is a participant in the Security Transfer Agents Medallion Program, the New

York Stock Exchange Medallion Signature Program or the Stock Exchange Medallion Program (generally a
member of a registered national securities exchange, a member of the Financial Industry Regulatory Authority, or a
commercial bank or trust company having an office in the United States);

·
tax waivers and any other instruments or documents that Barclays Bank PLC reasonably requires in order to

establish the validity of the beneficial ownership of the Notes and the claimant's entitlement to payment; and

·
any additional information Barclays Bank PLC requires to evidence satisfaction of any conditions to the exercise of

the Survivor's Option or to document beneficial ownership or authority to make the election and to cause the
repayment of the Notes.
In turn, the broker or other entity will deliver the completed Form of Notice and each of the above items to the trustee, and
the trustee will forward the Survivor's Option request to Barclays Bank PLC. The broker or other entity will be responsible
for disbursing payments received from the trustee, through the facilities of DTC, to the authorized representative of the
deceased beneficial owner. The Form of Notice may be obtained from Barclays Bank PLC, 745 Seventh Avenue, New York,
NY 10019, Attention: US-Syndicate, MTN Desk US, telephone: 212-412-1535.
During any time in which the Notes are not represented by a global note and are issued in definitive form:

·
all references in this section to participants and DTC, including the DTC's governing rules, regulations and procedures,
will be deemed inapplicable;

·
all determinations that the DTC participants are required to make as described in this section will be made by Barclays
Bank PLC, including, without limitation, determining whether the applicable decedent is in fact the beneficial owner of
the interest in the Notes to be redeemed or is in fact deceased and whether the representative is duly authorized to
request redemption on behalf of the applicable beneficial owner; and

·
all redemption requests, to be effective, must:

·
be delivered by the representative to Barclays Bank PLC and to the trustee;

·
be made by completing the Form of Notice in accordance with the related instructions; and

·
be accompanied by, if applicable, a properly executed assignment or endorsement, in addition to all
documents that are otherwise required to accompany a redemption request. If the record holder of the

Note is a nominee of the deceased beneficial owner, a certificate or letter from the nominee attesting to
the deceased's ownership of a beneficial interest in the Note must also be delivered.
Barclays Bank PLC retains the right to limit the aggregate principal amount of Notes as to which exercises of the Survivor's
Option will be accepted from all authorized representatives of deceased beneficial owners and from the authorized
representative for any individual deceased beneficial owner in any one calendar year as described above. All other questions
regarding the eligibility or validity of any exercise of the Survivor's Option generally will be determined by Barclays Bank
PLC, which determination will be final and binding on all parties.
UNITED STATES FEDERAL INCOME TAX TREATMENT
The following discussion supplements the discussion in the prospectus supplement under the heading "Certain U.S. Federal
Income Tax Considerations" and supersedes it to the extent inconsistent therewith. The following discussion (in conjunction
with the discussion in the prospectus supplement) summarizes certain of the material U.S. federal income tax consequences
of the purchase, beneficial ownership, and disposition of the Notes.
We intend to treat the Notes as indebtedness for U.S. federal income tax purposes and any reports to the Internal Revenue
Service (the "IRS") and U.S. holders will be consistent with such treatment, and each holder will agree to treat the Notes as
indebtedness for U.S. federal income tax purposes. The discussion that follows is based on this approach.

PS3
http://www.sec.gov/Archives/edgar/data/312070/000119312511096267/d424b2.htm
4/13/2011

Pricing Supplement 13Y 4.5% Fixed Note
Page 8 of 9
Interest paid on the Notes will be taxable to a U.S. holder as ordinary interest income at the time it accrues or is received in
accordance with the U.S. holder's normal method of accounting for tax purposes. See "U.S. Federal Income Tax
Considerations--Payments of Interest" in the prospectus supplement.
3.8% Medicare Tax On "Net Investment Income"
Beginning in 2013, U.S. holders that are individuals, estates, and certain trusts will be subject to an additional 3.8% tax on all
or a portion of their "net investment income," which may include the interest payments and any gain realized with respect to
the Notes, to the extent of their net investment income that when added to their other modified adjusted gross income,
exceeds $200,000 for an unmarried individual, $250,000 for a married taxpayer filing a joint return (or a surviving spouse),
or $125,000 for a married individual filing a separate return. U.S. holders should consult their advisors with respect to their
consequences with respect to the 3.8% Medicare tax.
Information Reporting
Holders that are individuals (and, to the extent provided in future regulations, entities) may be subject to certain foreign
financial asset reporting obligations with respect to their Notes if the aggregate value of their Notes and their other "specified
foreign financial assets" exceeds $50,000. Significant penalties can apply if a holder fails to disclose its specified foreign
financial assets. We urge you to consult your tax advisor with respect to this and other reporting obligations with respect to
your Notes.
CERTAIN EMPLOYEE RETIREMENT INCOME SECURITY ACT CONSIDERATIONS
Your purchase of a Note in an Individual Retirement Account (an "IRA"), will be deemed to be a representation and
warranty by you, as a fiduciary of the IRA and also on behalf of the IRA, that (i) neither the issuer, the placement agent nor
any of their respective affiliates has or exercises any discretionary authority or control or acts in a fiduciary capacity with
respect to the IRA assets used to purchase the Note or renders investment advice (within the meaning of Section 3(21)(A)(ii)
of the Employee Retirement Income Security Act ("ERISA")) with respect to any such IRA assets and (ii) in connection with
the purchase of the Note, the IRA will pay no more than "adequate consideration" (within the meaning of Section 408(b)(17)
of ERISA) and in connection with any redemption of the Note pursuant to its terms will receive at least adequate
consideration, and, in making the foregoing representations and warranties, you have (x) applied sound business principles in
determining whether fair market value will be paid, and (y) made such determination acting in good faith.
For additional ERISA considerations, see "Employee Retirement Income Security Act" in the prospectus supplement.
SUPPLEMENTAL PLAN OF DISTRIBUTION
We have agreed to sell to Barclays Capital Inc. (the "Agent"), and the Agent has agreed to purchase from us, the principal
amount of the Notes, and at the price, specified on the cover of this pricing supplement. The Agent is committed to take and
pay for all of the Notes, if any are taken.

PS4
http://www.sec.gov/Archives/edgar/data/312070/000119312511096267/d424b2.htm
4/13/2011

Pricing Supplement 13Y 4.5% Fixed Note
Page 9 of 9

US$71,000
BARCLAYS BANK PLC
4.50% FIXED RATE NOTES DUE APRIL 14, 2024
GLOBAL MEDIUM-TERM NOTES, SERIES A
(TO PROSPECTUS DATED AUGUST 31, 2010, AND THE
PROSPECTUS SUPPLEMENT DATED AUGUST 31, 2010)

http://www.sec.gov/Archives/edgar/data/312070/000119312511096267/d424b2.htm
4/13/2011